Occupational MDR-TB & me Reaching Zero TB Deaths and Zero New TB Infections Satellite Symposium, Kuala Lumpur, Malaysia Dalene and Arne von Delft13 November.

Slides:



Advertisements
Similar presentations
TUBERCULOSIS This is the prompt slide for the TB Therapy section.
Advertisements

The TB Alliance-Bayer Moxifloxacin Deal
TREATMENT OF TUBERCULOSIS, 2003
Daniel Everitt, MD; Erica Egizi MPH Global Alliance for TB Drug Development, New York Helen Winter, PhD University of Otago, New Zealand 2012 International.
Second-line Anti-TB drugs
Unit 8: Complications and Special Situations Botswana National Tuberculosis Programme Manual Training for Medical Officers.
New drugs and regimens for TB: 2015 update
Page 1 CPTR Workshop, Oct TB Drug Co-Development Roundtable Perspective from Bayer Dr. Martin Springsklee MD Head Global Medical Affairs Therapy.
TB Drug Co-Development Roundtable: TMC207 (bedaquiline) Chrispin Kambili, M.D. CPTR meeting Oct 04, To edit footers: "insert tab>header and footer"
Group II Treatment regimens, hospitalization. DOT provision, outcome definitions, management of adverse drug reactions.
Rationale for New Drugs for Tuberculosis 500,000 cases annually of MDR TB – Second line treatment toxic and weak 15% of TB is HIV-related – Drug-drug interactions.
XDR-TB and management options Ninth Technical Advisory Group and National TB Programme Managers Meeting TB Control in the Western Pacific Region, Manila,
CCEB Impact of HIV on Early MDR- TB Treatment Outcomes in Botswana Jeffrey Hafkin MD Botswana-UPenn Partnership Center for Clinical Epidemiology and Biostatistics.
Anti-tuberculous drugs. Mycobacteria Slow-growing bacillusDormant forms in macrophages.
Module 3: Drug-Resistant TB. Learning Objectives Describe how drug resistance emerges Explain the difference between primary and secondary resistance.
Richard Kohler, MD TB Consultant, Indiana State Department of Health Division of Infectious Diseases Indiana University School of Medicine.
Diagnosis and Management of TB John Yates Consultant Infectious Diseases.
TB. Areas of Concern TB cases continue to be reported in every state Drug-resistant cases reported in almost every state Estimated million persons.
Why do we test? 1.We want to prevent an outbreak of Tuberculosis in our campus community 2.We want to find those that are affected and get them treated.
Unit 5: IPT Isoniazid TB Preventive Therapy
4 th National Anti-tuberculosis Drug Resistance Survey Botswana, 2007.
Bedaquiline: Practical use and interim results in France Dr Mathilde Jachym 17 th of February Yerevan New treatments and approaches.
Molecular methods for TB drug resistance testing: what is needed? Experience from Khayelitsha, Cape Town, South Africa Helen Cox, PhD, Burnet Institute.
Reduced treatment delays for drug-resistant TB/HIV co-infected patients with decentralised care and rapid Xpert MTB/Rif test in Khayelitsha, South Africa.
Christoph Lange & Giovanni Sotgiu Principles of designing a TB and MDR-TB drug regimen.
Eight Week Randomized Trial of Treatment with Pa-824, Moxifloxacin, and Pyrazinamide in Drug Sensitive and Multi-Drug Resistant Tuberculosis July 21, 2014.
TB 101: TB Basics and Global Approaches. Objectives Review basic TB facts. Define common TB terms. Describe key global TB prevention and care strategies.
HAIVN Harvard Medical School AIDS Initiative in Vietnam
British Society for Microbial Technology The laboratory diagnosis of tuberculosis 25 years of progress D A Mitchison St George’s, University of London.
Elsevier Inc. items and derived items © 2010 by Saunders, an imprint of Elsevier Inc. Chapter 89 Antimycobacterial Agents: Drugs for Tuberculosis, Leprosy,
Tuberculosis Research of INA-RESPOND on Drug-resistant
Module 4 Basic Principles of Treatment. “ubo! ubo! ubo!” (cough for 2 weeks or more) Did not take medication medication In Loving Memory of In Loving.
Anri Uys (MSc Pharmacology, BPharm NWU) Medicines Information Centre, Division of Clinical Pharmacology University of Cape Town.
Thank you for viewing this presentation. We would like to remind you that this material is the property of the author. It is provided to you by the ERS.
TB 101 Part II Brenda Mayes, R. N. March TREATMENT TB DISEASE MDR XDR LATENT TB INFECTION.
Treatment of Tuberculosis: New Case Case Studies Module 7A2 – March 2010.
International Health Policy Program -Thailand Policy decision on multi drug resistant(MDR), extreme drug resistant(XDR) tuberculosis screening: How it.
Chemotherapy of Tuberculosis By Prof. Azza El-Medany.
TB Management: A Medical Aid Perspective presented by Dr Noluthando Nematswerani.
Tuberculosis August 17, 2010 Tuberculosis Mycobacterium tuberculosis – Fastidious, aerobic, acid-fast bacillus Tremendous increase in incidence over.
Unit 11 Drug Resistance and MDR-TB: B Family Case Botswana National Tuberculosis Programme Manual Training for Medical Officers.
Antitubercular Agents. Tuberculosis, “TB”Tuberculosis, “TB” Caused by Mycobacterium tuberculosisCaused by Mycobacterium tuberculosis Antitubercular agents.
By: Mpho Kontle and Topo Moses. Introduction & Etiology Multi-drug-resistant tuberculosis (MDR-TB) is defined as tuberculosis that is resistant to at.
Case Study Cloete van Vuuren ID Physician. 50 year old male Abscess over L parotid gland Cryptoccal meningitis 2010 PTB 2010 – completed 6/12 of Rx Stopped.
Christo van Niekerk, M.D. IUATLD Meeting, Cape Town December 5, 2015 TB Alliance Ongoing Clinical Trials in DS-, MDR-and XDR-TB.
MULTIDRUG- RESISTANT TUBERCULOSIS (MDR-TB) by Dr Mat Zuki Mat Jaeb 1.
Treatment Regimens for Pulmonary Tuberculosis Caused by Drug- Susceptible Organisms Initial PhaseContinuation Phase RegimenDrugs Interval and Doses (Minimal.
Roundtable. Detection and treatment of TB Andrew Black.
Depart. of Pulmonology R4 백승숙. 1. INTRODUCTION 2. BACKGROUND 3. DIAGNOSIS OF LATENT TB INFECTION 4. CHEMOPROPHYLAXIS 5. RISKS OF TUBERCULOSIS AND OF DRUG-INDUCED.
Tuberculosis in Children: Treatment and Monitoring Module 10B - March 2010.
Ward 5D Linda Iskandar 1. Patient MR From Nepal, has been in Australia for 2 years on a dependent student visa studying nursing. Presenting complaints.
Rifapentine-containing treatment shortening regimens for pulmonary tuberculosis UZ-UCSF ARD April 08, 2016 W.Samaneka MBChB, MSc Clin Epi, Dip HIV Man.
Comprehensive Treatment of Extensively Drug-Resistant Tuberculosis N Engl J Med 2008;359: R2 이 설 라.
Tuberculosis (TB) PHCL 442 Lab Discussion 4 Raniah Al-Jaizani M.Sc.
Treatment for Multi-drug Resistant TB
STREAM Trials Andrew Nunn MRC Clinical Trials Unit at UCL
STAND Trial NC-006 (M-Pa-Z) Dr Suzanne Staples Principal Investigator at THINK 26 Mar 2015.
Infant born with mother Tuberculosis
This is an archived document.
Safe and effective bedaquiline treatment of drug-resistant tuberculosis (DR-TB) within the National Bedaquiline Clinical Access Programme in South Africa.
William Burman Denver Public Health Tuberculosis Trials Consortium
Drug Resistant (DR) TB (Back to Basics)
Marie Turner, M.D. Jo-Ann Keegan, R.N., M.S.N.
Session 4: Expanded indications for bedaquiline and delamanid
24 July 2018 Treatment outcomes with bedaquiline use when substituted for second-line injectables in multidrug resistant tuberculosis: a retrospective.
Tuberculosis Control Program
Treatment of Drug Resistant TB - Questions
Presented by: Dr. Letshufi DSV 04th August 2016 Pretoria
Diversity of resistant and susceptible isolates.
Fig. 1. Antituberculosis drug resistance rate (%) and pattern in sanatoria of North Korea: (A) patients (n = 489) in all sanatoria analyzed in this study,
Presentation transcript:

Occupational MDR-TB & me Reaching Zero TB Deaths and Zero New TB Infections Satellite Symposium, Kuala Lumpur, Malaysia Dalene and Arne von Delft13 November 2012

Dalene von Delft MB.ChB South Africa, 2006 Completed 2 years internship and 1 year community service, – Medical Officer - Pediatrics Not TB proof after all?

WHO, 2009 Estimated TB incidence rates annually

Estimated HIV prevalence in new TB cases WHO, 2009

2 Days before Christmas, 2010 Difficult decision – Sputum microscopy negative (ZN negative) Options: 1.Occupational health specialist - Start empiric TB treatment and assess response 2.Private pulmonologist - CT with Bronchoscopy to find the organism

Results TestResultSensitivities Sputum microscopyZN negative Bronchoscopy specimen (bronchial washings) ZN positivePCR: Rifampicin Resistance PCR: Isoniazide Intermediate resistance 83% chance of Ethionamide resistance too PCR: Ethambutol Resistance PCR: Fluoroquinolones Sensitive PCR: Aminoglycosides Sensitive Saline induced sputum culture Positive after 27 days incubation only Same results as above plus: Ethionamide Sensitive (?) PZA: sensitive (initially reported as resistant?)

Genotyping (done on own initiative) Spoligotyping results: Beijing strain – Predominant drug resistant strain in the Western Cape – Also one of the dominant strains in susceptible TB rpoB S531L – most common mutation causing rifampicin resistance katG Wildtype, inhA promotor -15C→T – low level resistance against INH and most probably resistance to Ethionamide too. embB M306V – causes ethambutol resistance – controversy regarding the embB306 mutations in the literature – resident expert: does result in resistance, although the level unknown pncA wildtype (no mutation) – no resistance to pyrazinamide rpsL and rrs500 wildtype – no resistance to streptomycin gyrA wildtype – no resistance to fluoroquinolones rrs1400 wildtype – no resistance to Amikacin, Kanamycin or Capreomycin

Treatment Regime Isoniazide, 600mg daily (high dose) Amikacin, 1g daily IV Moxifloxacin, 400mg daily Pyrazinamide,1.5 g daily Ethionamide, 750mg daily Ethambutol, 800 mg daily Terizidone, 750mg daily o IM Sens Sens (?) o ?? ΧRes (?) o ?

Adverse effects Christmas in isolation

Adverse effects Adverse effectManagement Nausea and vomiting, loss of appetite - Day 1 Initially Metoclopramide Later changed to Ondansetron* Started taking treatment at night after 2 weeks to try and sleep through the nausea Diarrhea – Day 1Probiotics Peripheral Neuropathy – week 4High dose Pyridoxine (75mg daily) Vertigo and dizziness, extreme tiredness – 1st week Refrained from driving and working while symptoms present Insomnia – week 2 Depressed mood – week 4 After 4 months of no sleep at night, started Zolpidem 2,5mg nocte – great improvement in sleep and daily functioning (caution: suicide risk) Hypothyroidism ( hair loss) – w17Eltroxin Abdominal pain – w52Mildly raised liver enzymes Hyperuricaemia with arthralgia – w55Dietary adjustment Stopped Ethambutol after 14 months

Audiogram at baseline

Audiogram at 8 weeks

Audiogram at 10 weeks

Difficult decision – rather deaf than dead? “Un-informed consent” Seddon and Schaaf et al. Hearing loss in patients on treatment for drug‐resistant tuberculosis. ERJ Express. June – 61.5 % ototoxicity but differing methodology

Can anybody hear me? Occupational health nurse also had MDR TB – deaf overnight; one of two recent examples – Unable to use stethoscope despite bilateral cochlear implants – Music sounds like ‘tin’ I listened to music non-stop for days… Will I ever be able to practice as a clinician without a stethoscope? Peak and trough level monitoring – value? Genetic screening: susceptibility to aminoglycoside induced ototoxicity MT-RNR1 gene: negative for following mutations: – A827G, 961delT, T1095C, T1291C, C1494T and A1555G Also of limited value - patients who screen negative still develop hearing loss, just not as rapidly

No real options to choose from Why screen for hearing loss if no alternatives in any case? – Drug Holiday? Contentious: ?delaying the inevitable – Reduced dosing interval: no proven benefit * – Surgery: not for 1 st infection – Capreomycin: kept in “reserve” (but rrs1400 mutation affects kanamycin, amikacin and capreomycin?) Stop at own risk…what a “choice”! – Culture conversion within 2 weeks of treatment initiation with consecutive negative cultures – CXR improved rapidly – only fibrovascular scarring – Excellent compliance and support Hope of a back-up plan? *Peloquin et al. Aminoglycoside toxicity: daily versus thrice‐weekly dosing for treatment of mycobacterial diseases. Clin Infect Dis 2004

MDR-TB timeline - DvD w10…WHAT NOW? -16w, Aug 2010 Exposure? 0w, 24 Dec Dx 48h Resp unit w0-w10, Isolation Admission – Rx started 18 Feb Hearing loss: w8 Neg cult: w2 Arne Pleuritis Coughing /04/11 Submitted Ad -6w Infective? IV Amikacin Ethambutol INH (high) Ethionamide Terizidone Moxifloxacin PZA

The Diarylquinolone TMC207 (Bedaquiline) for MDR TB* Mechanism: – inhibits mycobacterial ATP synthase – in drug-sensitive and drug-resistant TB *Developed by Janssen - due for FDA approval 28 Nov 2012

Results of clinical trial – 24 weeks Significantly reduced the time to culture conversion over 24 weeks (hazard ratio, 2.253; 95% confidence interval, 1.08 to 4.71; P = 0.031)

MDR-TB timeline – unchartered territory w10, Amikacin stopped -16w, Aug 2010 Exposure? 0w, 24 Dec Dx 48h Resp unit w0-w10, Isolation Admission – Rx started 18 Feb Hearing loss: w8 Neg cult: w2 TMC 207/Bedaquiline application Hypothyroidism: w17 Gout: Ethambutol stopped w54 IGRA’s normal w81 CXR unchanged w34 Total treatment duration – 18.5 months Bedaquiline duration Arne Pleuritis Coughing Loading 2wks w28 – Bedaquiline started 28/12/10, d4 1 st enquiry w8, only XDR w18, CUP app’s open 11/04/11 Submitted w21 APPROVED w54,Bedaquiline completed Ad Mox, INH, Ethion, PZA, Teriz w81, Rx stopped, 18 m post-conv. X w46, MCC revokes CU -6w Infective? IV Amikacin Ethambutol INH (high) Ethionamide Terizidone Moxifloxacin PZA w10…WHAT NOW?

Adverse events QT prolongation? Patients received Ofloxacin. – Increases in the mean corrected QT interval were observed in both treatment groups but were more pronounced in the TMC207 group, with intergroup differences ranging from 1.0 to 10.8 msec (P>0.05). – None of the absolute values for corrected QT interval were greater than 500 msec, and no adverse events were associated with ECG changes.* Janssen 2010: Moxifloxacin use with bedaquiline was not advised pending more results *Andreas Diacon et al, NEJM June 2009

Average terminal elimination half-life of TMC207 is estimated as 132 days ECG not done at the same time or on same machine every day – Moxifloxacin peak and trough levels contributing to variability?

Compassionate use ‘Compassionate use’ allows for potentially lifesaving investigational drugs or experimental treatments (with good efficacy and safety in trials, but which haven’t been registered for market use) to be made available for patients suffering from a disease for which no satisfactory authorised therapy exists and/or who cannot enter a clinical trial. south-africa

MSF (and SA) vs. MCC July 2011: After discussions with MSF, Janssen submits request to the MCC for Section 21 compassionate use permission to use bedaquiline in the Khayelitsha DR-TB program for 6 month period August 2011: The MCC gives written approval for 6 month renewable Section 21 compassionate use in the Khayelitsha project November 2011: The MCC, in verbal communication to Janssen, revokes compassionate use permission – Reason? Dec 2011 – current: various attempts to regain access – MSF, SA HIV Clinicians Society, individual clinicians, Global Tuberculosis Community Advisory Board, AIDS & Rights Alliance for Southern Africa and TAC – Rejected two more times by MCC